Sofosbuvir‐velpatasvir‐voxilaprevir with or without ribavirin in direct‐acting antiviral–experienced patients with genotype 1 hepatitis C virus

Eric Lawitz, Fred Poordad, Jennifer Wells, Robert H. Hyland, Yin Yang, Hadas Dvory‐Sobol, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Carmen Landaverde, Julio Gutierrez – 21 February 2017 – The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1–infected patients who fail direct‐acting antiviral (DAA)‐based regimens remains unknown.

Living donor liver transplantation during the first 3 months of life

Mureo Kasahara, Seisuke Sakamoto, Kengo Sasaki, Hajime Uchida, Toshihiro Kitajima, Takanobu Shigeta, Soichi Narumoto, Yoshihiro Hirata, Akinari Fukuda – 21 February 2017 – Living donor liver transplantation (LDLT) is now an established technique for treating children with end‐stage liver disease. Few data exist about liver transplantation (LT) for exclusively young infants, especially infants of <3 months of age.

Subscribe to